Aryl ureas as kinase inhibitors

US9181188B2 · kind B2 · utility

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Jacques Dumas · Neuilly-Plaisance, FR
• William Scott · Guilford, US
• Du-Schieng Chien · Guilford, US
• Ala Nassar · Milford, US
• Wendy Lee · Hamden, US
• Susan Bjorge · Milford, US
• Laszlo L. Musza · New Haven, US
• Bernd Riedl · Wuppertal, DE

Key dates

• Filing date: Feb 3, 2012
• Grant date: Nov 10, 2015
• Expiry date: Feb 3, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D213/89
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.